Company: KNRX
Filing Date: 2025-03-05
Form Type: F-1/A
Source: 0001493152-25-009104
Chunk: 3

Company: KNOREX LTD.
Filing Date: 2025-03-05
Form: F-1/A
Chunk 3
---
SE American corporate governance rules as we do not currently expect that more than 50% of our voting power will be held by an individual, a group or another company immediately following the completion of this offering.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, and a “foreign private issuer” under applicable U.S. federal securities laws and, as such, are eligible for reduced public company reporting requirements. See “Prospectus Summary – Implications of Being an Emerging Growth Company” and “Prospectus Summary – Implications of Being a Foreign Private Issuer” beginning on page 8 of this prospectus for more information.

KNOREX LTD. was incorporated as an exempted company under the laws of the Cayman Islands without any operations of its own. We conduct our operations primarily in the United States, Singapore, Vietnam, India and Malaysia through our operating subsidiaries. The Class A ordinary shares offered in this offering are shares of the Cayman Islands holding company, instead of shares of our operating subsidiaries. Investors in this offering will not directly hold equity interests in our operating subsidiaries. This structure involves unique risks to investors. For a detailed discussion of risks associated with our corporate structure, see “Risk Factors – Risks Relating to Our Ordinary Shares and This Offering” beginning on page 28 of this prospectus.

You should read this prospectus, together with additional information described under the heading “Where You Can Find More Information,” carefully before you invest in any of our securities.

Investing in our securities involves a high degree of risks. See “Risk Factors” beginning on page 13 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                  |     | Per   
 Share |     | Total |
| Initial public offering price    |     | US$   |     | US$   |
| Underwriting discount and        
 commission(1)                    |     | US$   |     | US$   |
| Proceeds, before expenses, to us |     | US$   |     | US$   |

| (1) | For                                                                                           
 additional information on underwriting compensation, see “Underwriting” beginning on page 94. |
|     | We                                                                                            
 have granted